Insights
Levemir Discontinuation: What You Need to Know
Novo Nordisk, a global healthcare company, has recently announced the discontinuation of Levemir, a long-acting insulin, in the United States. This significant development, announced in
Beyond Unit Cost: Evaluating Clinical Programs and Capabilities of PBMs
Read the full article by AlignRx COO Greg Sanderson on Employee Benefit News. Drug pricing is typically the main factor brokers and employer groups consider
Medicaid AMP Cap Removal: Market Changes & Rx Strategies Amidst New Provisions
The ever-evolving pharmaceutical landscape is no stranger to reforms and regulations. With the recent changes brought about by the American Rescue Plan (ARP) of 2021,
AlignRx President & CEO Kevin Kobielski Recognized in 2023 BenefitsPRO Luminaries Awards
BenefitsPRO, the No.1 provider of news, analysis and trends for benefits professionals, has announced its 2023 Luminaries Awards recognizing excellence in the benefits industry. Kevin
AlignRx Consulting Recognized on the 2023 Inc. 5000 List of Fastest Growing Companies
Inc. revealed today that AlignRx Consulting ranks No. 898 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. The
The Cost Implications of New Weight Loss Treatments for Plan Sponsors
See this article by AlignRx chief pharmacy officer Beckie Fenrick as it originally appeared in BenefitsPRO. With obesity rates in the United States having tripled
Why Carve-Outs Happen And How To Prevent Them
See this article by AlignRx CEO Kevin Kobielski as it originally ran in Healthcare Business Today. Carve-outs can be a thorn in the side of
What Brokers and TPAs Need To Know About Humira Biosimilars
Below is an excerpt from an article by AlignRx chief pharmacy officer Beckie Fenrick and Goodroot area vice president of business development Brian Shonat that
A Shake Up in the U.S. Insulin Market: Major Manufacturers Lower Insulin Costs
A new trend in insulin pricing? Here’s what you need to know. Insulin pricing has been a topic of concern and debate in recent years,
Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars
The industry report you’ve been waiting for. Today biosimilars seem to be the topic of conversation everywhere. Why? Humira. The launch of Humira biosimilars will be
AlignRx Highlighted on Self-Funded with Spencer Podcast
Brian Shonat, Goodroot’s area vice president of business development, recently joined Spencer Smith on the Self-Funded with Spencer podcast to talk AlignRx, PBM contracts, specialty
Webinar on Demand: Meeting the Mandate—The TPA Path to RxDC Success
The RxDC Reporting Deadline is Approaching—Are you Prepared? At AlignRx, we provide our valued TPA partners and their employer groups with year-round pharmacy consulting and
RxDC TPA Guide – What TPAs Need to Know
The RxDC Reporting Deadline Is Approaching—Are You Prepared? The Consolidated Appropriations Act has a new Rx mandate for your employer groups and the deadline is
5 Must-ask Questions Before the PBM RFP Process
Read the full article by AlignRx COO Greg Sanderson on Employee Benefit News. While it may seem early to be thinking about 2023, summer is
How Specialty Drug ‘Solution Stacking’ Can Rein in Pharmacy Benefit Costs
Brokers and employer groups alike know that 5% to 10% percent of insured workers and their dependents drive 50% to 60% of the cost of
Prediabetes and Type 2 Diabetes Screening
What is happening: In August 2021 the United States Preventive Services Task Force (USPSTF) recommended that adults, aged 35 to 70 years who are overweight
Stay Connected
"(Required)" indicates required fields
